Card image cap
Transdermal patch, Adlarity, approved for AD-linked dementia

The US FDA has approved once-weekly use of Adlarity, a transdermal patch of donepezil, in 5 mg/day or 10 mg/day formulations to treat patients with mild, moderate or severe dementia associated with Alzheimer’s Disease (AD). The patch, which can be placed by a patient or caregiver on a patient’s back, thigh or buttocks, delivers a consistent dose of donepezil through the skin, resulting in a low likelihood of adverse gastrointestinal side effects associated with oral donepezil. Patients may be switched from 5 mg/day or 10 mg/day oral donepezil directly to Adlarity by their prescriber. Adlarity is a brand of Corium Inc, a US-based biopharmaceutical company.

Elevate your practice with our advanced AI-based CDSS Tool.Transform your practice now!

Disclaimer :
The author(s)' thoughts and opinions in this article are their own and do not necessarily reflect DocMode's viewpoint. The article is in no way created or edited by DocMode.

Submit a Comment